Immunosignature differentiation of non-infectious meningoencephalomyelitis and intracranial neoplasia in dogs

Bathilda B. Lake, John Henry Rossmeisl, Julie Cecere, Phillip Stafford, Kurt L. Zimmerman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A variety of inflammatory conditions of unknown cause (meningoencephalomyelitis of unknown etiology-MUE) and neoplastic diseases can affect the central nervous system (CNS) of dogs. MUE can mimic intracranial neoplasia both clinically, radiologically and even in some cases, histologically. Serum immunosignature protein microarray assays have been used in humans to identify CNS diseases such as Alzheimer's and neoplasia, and in dogs, to detect lymphoma and its progression. This study evaluated the effectiveness of immunosignature profiles for distinguishing between three cohorts of dogs: healthy, intracranial neoplasia, and MUE. Using the learned peptide patterns for these three cohorts, classification prediction was evaluated for the same groups using a 10-fold cross validation methodology. Accuracy for classification was 100%, as well as 100% specific and 100% sensitive. This pilot study demonstrates that immunosignature profiles may help serve as a minimally invasive tool to distinguish between MUE and intracranial neoplasia in dogs.

Original languageEnglish (US)
Article number97
JournalFrontiers in Veterinary Science
Volume5
Issue numberMAY
DOIs
StatePublished - May 11 2018

Fingerprint

meningoencephalitis
Dogs
neoplasms
dogs
Neoplasms
central nervous system diseases
Protein Array Analysis
Central Nervous System Diseases
lymphoma
blood proteins
central nervous system
etiology
Blood Proteins
Lymphoma
Central Nervous System
peptides
Peptides
prediction
assays
methodology

Keywords

  • Canine
  • Immunosignature
  • Intracranial neoplasia
  • Meningoencephalomyelitis of unknown etiology
  • Peptide microarray

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Immunosignature differentiation of non-infectious meningoencephalomyelitis and intracranial neoplasia in dogs. / Lake, Bathilda B.; Rossmeisl, John Henry; Cecere, Julie; Stafford, Phillip; Zimmerman, Kurt L.

In: Frontiers in Veterinary Science, Vol. 5, No. MAY, 97, 11.05.2018.

Research output: Contribution to journalArticle

Lake, Bathilda B. ; Rossmeisl, John Henry ; Cecere, Julie ; Stafford, Phillip ; Zimmerman, Kurt L. / Immunosignature differentiation of non-infectious meningoencephalomyelitis and intracranial neoplasia in dogs. In: Frontiers in Veterinary Science. 2018 ; Vol. 5, No. MAY.
@article{374b5b22e3124a77b1efd0136442608f,
title = "Immunosignature differentiation of non-infectious meningoencephalomyelitis and intracranial neoplasia in dogs",
abstract = "A variety of inflammatory conditions of unknown cause (meningoencephalomyelitis of unknown etiology-MUE) and neoplastic diseases can affect the central nervous system (CNS) of dogs. MUE can mimic intracranial neoplasia both clinically, radiologically and even in some cases, histologically. Serum immunosignature protein microarray assays have been used in humans to identify CNS diseases such as Alzheimer's and neoplasia, and in dogs, to detect lymphoma and its progression. This study evaluated the effectiveness of immunosignature profiles for distinguishing between three cohorts of dogs: healthy, intracranial neoplasia, and MUE. Using the learned peptide patterns for these three cohorts, classification prediction was evaluated for the same groups using a 10-fold cross validation methodology. Accuracy for classification was 100{\%}, as well as 100{\%} specific and 100{\%} sensitive. This pilot study demonstrates that immunosignature profiles may help serve as a minimally invasive tool to distinguish between MUE and intracranial neoplasia in dogs.",
keywords = "Canine, Immunosignature, Intracranial neoplasia, Meningoencephalomyelitis of unknown etiology, Peptide microarray",
author = "Lake, {Bathilda B.} and Rossmeisl, {John Henry} and Julie Cecere and Phillip Stafford and Zimmerman, {Kurt L.}",
year = "2018",
month = "5",
day = "11",
doi = "10.3389/fvets.2018.00097",
language = "English (US)",
volume = "5",
journal = "Frontiers in Veterinary Science",
issn = "2297-1769",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

TY - JOUR

T1 - Immunosignature differentiation of non-infectious meningoencephalomyelitis and intracranial neoplasia in dogs

AU - Lake, Bathilda B.

AU - Rossmeisl, John Henry

AU - Cecere, Julie

AU - Stafford, Phillip

AU - Zimmerman, Kurt L.

PY - 2018/5/11

Y1 - 2018/5/11

N2 - A variety of inflammatory conditions of unknown cause (meningoencephalomyelitis of unknown etiology-MUE) and neoplastic diseases can affect the central nervous system (CNS) of dogs. MUE can mimic intracranial neoplasia both clinically, radiologically and even in some cases, histologically. Serum immunosignature protein microarray assays have been used in humans to identify CNS diseases such as Alzheimer's and neoplasia, and in dogs, to detect lymphoma and its progression. This study evaluated the effectiveness of immunosignature profiles for distinguishing between three cohorts of dogs: healthy, intracranial neoplasia, and MUE. Using the learned peptide patterns for these three cohorts, classification prediction was evaluated for the same groups using a 10-fold cross validation methodology. Accuracy for classification was 100%, as well as 100% specific and 100% sensitive. This pilot study demonstrates that immunosignature profiles may help serve as a minimally invasive tool to distinguish between MUE and intracranial neoplasia in dogs.

AB - A variety of inflammatory conditions of unknown cause (meningoencephalomyelitis of unknown etiology-MUE) and neoplastic diseases can affect the central nervous system (CNS) of dogs. MUE can mimic intracranial neoplasia both clinically, radiologically and even in some cases, histologically. Serum immunosignature protein microarray assays have been used in humans to identify CNS diseases such as Alzheimer's and neoplasia, and in dogs, to detect lymphoma and its progression. This study evaluated the effectiveness of immunosignature profiles for distinguishing between three cohorts of dogs: healthy, intracranial neoplasia, and MUE. Using the learned peptide patterns for these three cohorts, classification prediction was evaluated for the same groups using a 10-fold cross validation methodology. Accuracy for classification was 100%, as well as 100% specific and 100% sensitive. This pilot study demonstrates that immunosignature profiles may help serve as a minimally invasive tool to distinguish between MUE and intracranial neoplasia in dogs.

KW - Canine

KW - Immunosignature

KW - Intracranial neoplasia

KW - Meningoencephalomyelitis of unknown etiology

KW - Peptide microarray

UR - http://www.scopus.com/inward/record.url?scp=85046847185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046847185&partnerID=8YFLogxK

U2 - 10.3389/fvets.2018.00097

DO - 10.3389/fvets.2018.00097

M3 - Article

AN - SCOPUS:85046847185

VL - 5

JO - Frontiers in Veterinary Science

JF - Frontiers in Veterinary Science

SN - 2297-1769

IS - MAY

M1 - 97

ER -